Michelle Kramer

Statistics

Publications

Citations

2.5K

H-Index

Active since

2002

Affiliations

Johnson & Johnson (United States)(Current)

Janssen (United States)

Janssen (Belgium)

Michelle Kramer is an author at Johnson & Johnson (United States) specializing in psychopharmacology, pharmacotherapy, and antipsychotic pharmacotherapy.

ORCID

Publications per year

2002–2020

Publications

Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial☆

John M. Kane, F. Cañas, Michelle Kramer et al. · Schizophrenia Research · 2006 · 297 citations

Pharmacy, Pharmacotherapy, Psychiatry +12

Rapid Antimanic Effect of Risperidone Monotherapy: A 3-Week Multicenter, Double-Blind, Placebo-Controlled Trial

Robert M. A. Hirschfeld, Paul E. Keck, Michelle Kramer et al. · American Journal of Psychiatry · 2004 · 273 citations

Pharmacy, Pharmacotherapy, Psychiatry +17

Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study

Michael Davidson, Robin Emsley, Michelle Kramer et al. · Schizophrenia Research · 2007 · 252 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study

Stephen R. Marder, Michelle Kramer, Lisa Ford et al. · Biological Psychiatry · 2007 · 234 citations

Pharmacy, Pharmacology, Pharmacotherapy +10

Paliperidone Extended-Release Tablets for Prevention of Symptom Recurrence in Patients With Schizophrenia

Michelle Kramer, George M. Simpson, Valentinas Mačiulis et al. · Journal of Clinical Psychopharmacology · 2007 · 224 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

1–5 of 19